Abstract
Purpose The 74th World Health Assembly endorsed a global target for 30% increase in effective cataract surgery coverage (eCSC) from 2020 to 2030. The current study was conducted to help monitoring the progress in the next decade in China.
Design A cross-sectional multi-center study, the China National Eye Health Survey (CNEHS), was conducted from 2021 to 2022 and covered 562 communities/villages from 12 representative provinces in China.
Methods This study is based on participants who were at least 50 years of years in the CNEHS. eCSC estimates the proportion of individuals with operated cataract achieving postoperative visual acuity ≥6/18 out of the total population including both operated and operable cataract cases. Both the CSC and eCSC were adjusted for age and sex.
Results A total of 45,051 participants were included in the analysis. The standardized incidence of vision impairment and blindness (best-corrected visual acuity in the better eye <6/18) was 4.4% (95% CI, 4.2%-4.6%). Cataracts accounted for 52.7% of these cases. The weighted rates of CSC and eCSC were 57.2% (95% CI, 47.6%-66.8%) and 38.7% (95% CI, 31.7%-45.6%), respectively. Contributing factors to the quality gap(difference between CSC and eCSC) included concurrent ocular diseases (62.2%) and complications relevant to surgery. CSC increased by 38.9% and eCSC by 26.1% over the decade. Both CSC and eCSC varied substantially across the 12 provinces (range: 41.2%-87.3% for CSC; 16.7%-71.0% for eCSC). Pearson correlation analysis indicated that regional disparities were primarily explained by the level of medical resource allocation, particularly the number of physicians or ophthalmologists per unit population (r=0.6, p=0.03).
Conclusion During the 2021-2022 period, CSC and eCSC rates in China were 57.2% and 38.7%, respectively. Regional disparity in cataract coverage were observed and correlated with the level of medical resources allocation.
WHAT IS ALREADY KNOWN ON THIS TOPIC The latest national epidemiological data on cataract surgical coverage in China dates back to 2014 and contains limited information.
WHAT THIS STUDY ADDS Between 2021 and 2022, the rates of CSC and eCSC in China were 57.2% and 38.7% at the 6/18 threshold, respectively. Comparing this with historical data reveals a significant improvement, with eCSC increasing by 26.1% over the past decade. However, there remains a notable quality gap, largely due to concurrent ocular diseases (62.2%), which should not be included in the eCSC measure. Additionally, substantial regional disparities were identified, with eCSC rates varying from 16.7% to 71.0% across the 12 surveyed provinces/municipalities. These disparities are primarily linked to the distribution of medical resources per capita rather than economic status.
HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY Despite significant improvements over the past decade, CSC and eCSC rates in China remain lower than those reported in most other countries. To address this, the government is urged to allocate more medical resources to less developed regions. Furthermore, the definition of eCSC should be revisited to exclude biases from concurrent ocular diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Beijing Tongren Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
